Drug Trial News

RSS

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

9 Dec 2009

Phase II clinical trial results of Doxorubicin Transdrug announced

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces positive survival data in its phase II clinical trial with doxorubicin Transdrug® in patients with advanced hepatocellular carcinoma (primary liver cancer).

9 Dec 2009

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.

9 Dec 2009

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, has completed a Phase 3 clinical trial of Lymphoseek® (NEO3-05) with positive results.

9 Dec 2009

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company’s oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.

8 Dec 2009

Micromet presents final data from its blinatumomab Phase 2 study for ALL

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL).

8 Dec 2009

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

The National Fragile X Foundation has awarded a translational research seed grant of $100,000 to Dr. Randi J. Hagerman at the UC Davis M.I.N.D. Institute in California for a study of minocycline in the treatment of children with fragile X syndrome (FXS). Hagerman is an internationally recognized clinician and clinical researcher on FXS, the most common cause of inherited mental impairment.

8 Dec 2009

Updated data from Allos Therapeutics' ongoing FOLOTYN study

Allos Therapeutics, Inc. today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). These data were showcased during an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA.

8 Dec 2009

Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia

HemaQuest Pharmaceuticals presented data from new preclinical studies and early results from clinical trials of its lead drug candidate, HQK-1001, in sickle cell disease and beta thalassemia at the annual meeting of the American Society of Hematology in New Orleans.

8 Dec 2009

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.

8 Dec 2009

Interim data from Geron's GRNVAC1 phase II trial for AML presented

Geron Corporation today announced the presentation of interim data from its phase II trial of GRNVAC1, an autologous dendritic cell vaccine targeting telomerase, in patients with acute myelogenous leukemia (AML) at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

8 Dec 2009

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.

8 Dec 2009

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). The VELCADE based combinations evaluated in the study demonstrated two-year overall survival rates ranging between 81 and 88 percent.

8 Dec 2009

$Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma$

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib.

8 Dec 2009

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Celgene International Sàrl announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma were presented during the American Society of Hematology’s annual meeting in New Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone prolonged time to progression, including complete responses, with manageable toxicity.

8 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Onconova Therapeutics, Inc. today announced promising results from two clinical trials in patients with advanced Myelodysplastic Syndrome (MDS) treated with ON 01910.Na. These trials are being conducted at the National Heart, Lung, and Blood Institute (NHLBI) in Bethesda, MD, and St. Vincent’s Comprehensive Cancer Center in New York.

8 Dec 2009

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

ARIAD Pharmaceuticals, Inc. today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers.

8 Dec 2009

SOLESTA pivotal study meets primary endpoints for fecal incontinence treatment

Q-Med AB and Oceana Therapeutics, Inc. today announced that the SOLESTA pivotal study succeeded in meeting both primary endpoints for the treatment of fecal incontinence.

8 Dec 2009

Drug Trial News

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Phase II clinical trial results of Doxorubicin Transdrug announced

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Micromet presents final data from its blinatumomab Phase 2 study for ALL

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

Updated data from Allos Therapeutics' ongoing FOLOTYN study

Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Interim data from Geron's GRNVAC1 phase II trial for AML presented

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

SOLESTA pivotal study meets primary endpoints for fecal incontinence treatment

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News